Medicare Enrolled

Dr. Mark Walberg, M.D.

Medical Oncology · Dallas, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
3410 WORTH ST, Dallas, TX 75246
2143701000
In practice since 2006 (19 years)
NPI: 1306884333 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Walberg from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Walberg? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Walberg

Dr. Mark Walberg is a medical oncology in Dallas, TX, with 19 years in practice. Based on federal Medicare data, Dr. Walberg performed 69,909 Medicare services across 1,757 unique beneficiaries.

Between the years covered by Open Payments, Dr. Walberg received a total of $581 from 15 pharmaceutical and/or device companies across 28 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Walberg is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 15% volume in TX$ $581 industry payments

Medicare Practice Summary

Medicare Utilization ↗
69,909
Medicare services
Top 15% in TX for medical oncology
1,757
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,679 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Pembrolizumab injection (Keytruda)13,400$43$136
Anti-nausea injection (fosaprepitant)12,000$0$5
Iron infusion (Feraheme)7,140$0$5
Paclitaxel chemotherapy injection6,517$0$8
Nivolumab injection (Opdivo)5,940$24$77
Iron sucrose injection (Venofer)5,700$0$2
Oxaliplatin chemotherapy injection4,400$0$33
Contrast dye for imaging (iodine-based)4,209$0$3
Daratumumab injection (Darzalex)3,600$38$128
Dexamethasone injection (steroid)1,862$0$1
Anti-nausea injection (Aloxi/palonosetron)1,200$1$114
Injection, granisetron hydrochloride, 100 mcg570$0$24
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less360$23$157
Injection, leucovorin calcium, per 50 mg328$3$25
Administration of chemotherapy into vein, 1 hour or less278$105$707
Injection, fluorouracil, 500 mg242$2$13
Injection of additional new drug or substance into vein239$12$108
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg227$3$373
Injection, carboplatin, 50 mg186$2$300
Injection, magnesium sulfate, per 500 mg158$1$6
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg156$68$1,348
Injection, zoledronic acid, 1 mg117$7$431
Office visit, established patient (30-39 min)95$92$368
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less90$49$313
Administration of additional new drug or substance into vein, 1 hour or less86$52$344
Injection, diphenhydramine hcl, up to 50 mg84$1$7
Unclassified drugs69$1$8
Blood draw (venipuncture)67$8$20
Comprehensive metabolic blood panel67$10$64
Complete blood count (CBC) with differential56$8$36
Infusion, normal saline solution , 1000 cc51$2$19
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion50$16$94
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle50$57$211
Ct scan of chest with contrast41$62$821
Administration of chemotherapy into vein, each additional hour40$23$161
Hospital follow-up visit, moderate complexity36$62$247
CT scan of abdomen and pelvis with contrast34$182$1,067
Drug injection, under skin or into muscle34$11$96
Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l26$135$500
Infusion into a vein for hydration, each additional hour21$10$75
Administration of additional new drug or substance into vein using push technique20$44$289
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour19$16$100
Office visit, established patient, complex (40-54 min)17$121$496
CT scan of chest, without contrast14$53$686
Application of on-body injector for under skin injection13$15$96
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
11.1% high complexity
88.2% medium
0.7% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$581
Total received (2020-2024)
Avg $116/year across 5 years
Bottom 24% in TX for medical oncology
15
Companies
28
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$569 (97.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$12 (2.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$299
2023
$200
2022
$19
2021
$43
2020
$19

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Eisai Inc.
$87
AstraZeneca Pharmaceuticals LP
$81
Incyte Corporation
$53
Bayer Healthcare Pharmaceuticals Inc.
$47
Seagen Inc.
$47
ARRAY BIOPHARMA INC
$44
Astellas Pharma US Inc
$40
PFIZER INC.
$38
Tempus AI, Inc
$30
Aveo Pharmaceuticals, Inc.
$24
Sun Pharmaceutical Industries Inc.
$23
Bayer HealthCare Pharmaceuticals Inc.
$19
Merck Sharp & Dohme LLC
$19
Regeneron Healthcare Solutions, Inc.
$17
Gilead Sciences, Inc.
$12
Top 3 companies account for 38.0% of total payments
Associated products mentioned in payments ›
BRAFTOVI · FOTIVDA · IMFINZI · IMJUDO · INLYTA · KEYTRUDA · LIBTAYO · Lenvima · MONJUVI · Nubeqa · Odomzo · PADCEV · Padcev · TUKYSA · XALKORI · XTANDI
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $1 per 100 Medicare services performed
Looking for a medical oncology in Dallas?
Compare medical oncologys in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
90
Per 100K population
3.5
County median income
$74,149
Nearest hospital
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Walberg is a mixed practice specialist, with above-average Medicare volume (top 15% in TX), and low-engagement industry engagement, with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Walberg experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Walberg performed 13,400 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Walberg receive payments from pharmaceutical companies?
Yes. Dr. Walberg received a total of $581 from 15 companies across 28 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Walberg's costs compare to other medical oncologys in Dallas?
Dr. Walberg's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Walberg) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →